AustralieFrV1, Main, Exploration, bibRecord, 00AB60

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer

Identifieur interne : 00AB60 ( Main/Exploration ); précédent : 00AB59; suivant : 00AB61

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer

Auteurs : Thierry Andre [France] ; Corrado Boni [Italie] ; Lamia Mounedji-Boudiaf [France] ; Matilde Navarro [Espagne] ; Josep Tabernero [Espagne] ; Tamas Hickish [Royaume-Uni] ; Clare Topham [Royaume-Uni] ; Marta Zaninelli [Italie] ; Philip Clingan [Australie] ; John Bridgewater [Royaume-Uni] ; Isabelle Tabah-Fisch [France] ; Aimery De Gramont [France]

Source :

The New England journal of medicine [ 0028-4793 ] ; 2004.

RBID : Pascal:04-0317626

Descripteurs français

Pascal (Inist)
- Oxaliplatine, Fluorouracil, Folinate de calcium, Traitement adjuvant, Médecine, Cancer du côlon.
Wicri :
- topic : Médecine.

English descriptors

KwdEn :
- Adjuvant treatment, Calcium folinate, Colon cancer, Fluorouracil, Medicine, Oxaliplatin.

Abstract

BACKGROUND The standard adjuvant treatment of colon cancer is fluorouracil plus leucovorin (FL). Oxaliplatin improves the efficacy of this combination in patients with metastatic colorectal cancer. We evaluated the efficacy of treatment with FL plus oxaliplatin in the postoperative adjuvant setting. METHODS We randomly assigned 2246 patients who had undergone curative resection for stage II or III colon cancer to receive FL alone or with oxaliplatin for six months. The primary end point was disease-free survival. RESULTS A total of 1123 patients were randomly assigned to each group. After a median follow-up of 37.9 months, 237 patients in the group given FL plus oxaliplatin had had a cancer-related event, as compared with 293 patients in the FL group (21.1 percent vs. 26.1 percent; hazard ratio for recurrence, 0.77; P=0.002). The rate of disease-free survival at three years was 78.2 percent (95 percent confidence interval, 75.6 to 80.7) in the group given FL plus oxaliplatin and 72.9 percent (95 percent confidence interval, 70.2 to 75.7) in the FL group (P=0.002 by the stratified log-rank test). In the group given FL plus oxaliplatin, the incidence of febrile neutropenia was 1.8 percent, the incidence of gastrointestinal adverse effects was low, and the incidence of grade 3 sensory neuropathy was 12.4 percent during treatment, decreasing to 1.1 percent at one year of follow-up. Six patients in each group died during treatment (death rate, 0.5 percent). CONCLUSIONS Adding oxaliplatin to a regimen of fluorouracil and leucovorin improves the adjuvant treatment of colon cancer.

Affiliations:

Australie, Espagne, France, Italie, Royaume-Uni
Angleterre, Catalogne, Grand Londres, Île-de-France
Barcelone, Londres, Paris

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 004E65
to stream PascalFrancis, to step Curation: 001249
to stream PascalFrancis, to step Checkpoint: 004A20
to stream Main, to step Merge: 00B847
to stream Main, to step Curation: 00AB60

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer</title>
<author><name sortKey="Andre, Thierry" sort="Andre, Thierry" uniqKey="Andre T" first="Thierry" last="Andre">Thierry Andre</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Hôpital Tenon</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>GERCOR Oncology Multidisciplinary Group</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Boni, Corrado" sort="Boni, Corrado" uniqKey="Boni C" first="Corrado" last="Boni">Corrado Boni</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Arcispedale Santa Maria Nuova</s1>
<s2>Reggio Emilia</s2>
<s3>ITA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>Arcispedale Santa Maria Nuova</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mounedji Boudiaf, Lamia" sort="Mounedji Boudiaf, Lamia" uniqKey="Mounedji Boudiaf L" first="Lamia" last="Mounedji-Boudiaf">Lamia Mounedji-Boudiaf</name>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Sanofi-Synthelabo</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Navarro, Matilde" sort="Navarro, Matilde" uniqKey="Navarro M" first="Matilde" last="Navarro">Matilde Navarro</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Hospital Duran i Reynals, l'Hospitalet de Llobregat</s1>
<s2>Llobregat</s2>
<s3>ESP</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Espagne</country>
<wicri:noRegion>Llobregat</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Tabernero, Josep" sort="Tabernero, Josep" uniqKey="Tabernero J" first="Josep" last="Tabernero">Josep Tabernero</name>
<affiliation wicri:level="3"><inist:fA14 i1="06"><s1>Vall d'Hebron University Hospital</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Espagne</country>
<placeName><settlement type="city">Barcelone</settlement>
<region nuts="2" type="region">Catalogne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hickish, Tamas" sort="Hickish, Tamas" uniqKey="Hickish T" first="Tamas" last="Hickish">Tamas Hickish</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Dorset Cancer Centre, Royal Bournemouth and Poole Hospitals</s1>
<s2>Bournemouth</s2>
<s3>GBR</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Bournemouth</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Topham, Clare" sort="Topham, Clare" uniqKey="Topham C" first="Clare" last="Topham">Clare Topham</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Royal Surrey County Hospital</s1>
<s2>Guildford, Surrey</s2>
<s3>GBR</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Royal Surrey County Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Zaninelli, Marta" sort="Zaninelli, Marta" uniqKey="Zaninelli M" first="Marta" last="Zaninelli">Marta Zaninelli</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Ospedale Borgotrento</s1>
<s2>Verona, Southern</s2>
<s3>ITA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>Ospedale Borgotrento</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Clingan, Philip" sort="Clingan, Philip" uniqKey="Clingan P" first="Philip" last="Clingan">Philip Clingan</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Medical Day Care Centre</s1>
<s2>Wollongong</s2>
<s3>AUS</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Medical Day Care Centre</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bridgewater, John" sort="Bridgewater, John" uniqKey="Bridgewater J" first="John" last="Bridgewater">John Bridgewater</name>
<affiliation wicri:level="3"><inist:fA14 i1="11"><s1>North Middlesex Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tabah Fisch, Isabelle" sort="Tabah Fisch, Isabelle" uniqKey="Tabah Fisch I" first="Isabelle" last="Tabah-Fisch">Isabelle Tabah-Fisch</name>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Sanofi-Synthelabo</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="De Gramont, Aimery" sort="De Gramont, Aimery" uniqKey="De Gramont A" first="Aimery" last="De Gramont">Aimery De Gramont</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>GERCOR Oncology Multidisciplinary Group</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="12"><s1>Hôpital Saint-Antoine</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">04-0317626</idno>
<date when="2004">2004</date>
<idno type="stanalyst">PASCAL 04-0317626 INIST</idno>
<idno type="RBID">Pascal:04-0317626</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">004E65</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001249</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">004A20</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">004A20</idno>
<idno type="wicri:doubleKey">0028-4793:2004:Andre T:oxaliplatin:fluorouracil:and</idno>
<idno type="wicri:Area/Main/Merge">00B847</idno>
<idno type="wicri:Area/Main/Curation">00AB60</idno>
<idno type="wicri:Area/Main/Exploration">00AB60</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer</title>
<author><name sortKey="Andre, Thierry" sort="Andre, Thierry" uniqKey="Andre T" first="Thierry" last="Andre">Thierry Andre</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Hôpital Tenon</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>GERCOR Oncology Multidisciplinary Group</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Boni, Corrado" sort="Boni, Corrado" uniqKey="Boni C" first="Corrado" last="Boni">Corrado Boni</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Arcispedale Santa Maria Nuova</s1>
<s2>Reggio Emilia</s2>
<s3>ITA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>Arcispedale Santa Maria Nuova</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mounedji Boudiaf, Lamia" sort="Mounedji Boudiaf, Lamia" uniqKey="Mounedji Boudiaf L" first="Lamia" last="Mounedji-Boudiaf">Lamia Mounedji-Boudiaf</name>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Sanofi-Synthelabo</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Navarro, Matilde" sort="Navarro, Matilde" uniqKey="Navarro M" first="Matilde" last="Navarro">Matilde Navarro</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Hospital Duran i Reynals, l'Hospitalet de Llobregat</s1>
<s2>Llobregat</s2>
<s3>ESP</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Espagne</country>
<wicri:noRegion>Llobregat</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Tabernero, Josep" sort="Tabernero, Josep" uniqKey="Tabernero J" first="Josep" last="Tabernero">Josep Tabernero</name>
<affiliation wicri:level="3"><inist:fA14 i1="06"><s1>Vall d'Hebron University Hospital</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Espagne</country>
<placeName><settlement type="city">Barcelone</settlement>
<region nuts="2" type="region">Catalogne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hickish, Tamas" sort="Hickish, Tamas" uniqKey="Hickish T" first="Tamas" last="Hickish">Tamas Hickish</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Dorset Cancer Centre, Royal Bournemouth and Poole Hospitals</s1>
<s2>Bournemouth</s2>
<s3>GBR</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Bournemouth</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Topham, Clare" sort="Topham, Clare" uniqKey="Topham C" first="Clare" last="Topham">Clare Topham</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Royal Surrey County Hospital</s1>
<s2>Guildford, Surrey</s2>
<s3>GBR</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Royal Surrey County Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Zaninelli, Marta" sort="Zaninelli, Marta" uniqKey="Zaninelli M" first="Marta" last="Zaninelli">Marta Zaninelli</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Ospedale Borgotrento</s1>
<s2>Verona, Southern</s2>
<s3>ITA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>Ospedale Borgotrento</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Clingan, Philip" sort="Clingan, Philip" uniqKey="Clingan P" first="Philip" last="Clingan">Philip Clingan</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Medical Day Care Centre</s1>
<s2>Wollongong</s2>
<s3>AUS</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Medical Day Care Centre</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bridgewater, John" sort="Bridgewater, John" uniqKey="Bridgewater J" first="John" last="Bridgewater">John Bridgewater</name>
<affiliation wicri:level="3"><inist:fA14 i1="11"><s1>North Middlesex Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tabah Fisch, Isabelle" sort="Tabah Fisch, Isabelle" uniqKey="Tabah Fisch I" first="Isabelle" last="Tabah-Fisch">Isabelle Tabah-Fisch</name>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Sanofi-Synthelabo</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="De Gramont, Aimery" sort="De Gramont, Aimery" uniqKey="De Gramont A" first="Aimery" last="De Gramont">Aimery De Gramont</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>GERCOR Oncology Multidisciplinary Group</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="12"><s1>Hôpital Saint-Antoine</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">The New England journal of medicine</title>
<title level="j" type="abbreviated">N. Engl. j. med.</title>
<idno type="ISSN">0028-4793</idno>
<imprint><date when="2004">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">The New England journal of medicine</title>
<title level="j" type="abbreviated">N. Engl. j. med.</title>
<idno type="ISSN">0028-4793</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvant treatment</term>
<term>Calcium folinate</term>
<term>Colon cancer</term>
<term>Fluorouracil</term>
<term>Medicine</term>
<term>Oxaliplatin</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Oxaliplatine</term>
<term>Fluorouracil</term>
<term>Folinate de calcium</term>
<term>Traitement adjuvant</term>
<term>Médecine</term>
<term>Cancer du côlon</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Médecine</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">BACKGROUND The standard adjuvant treatment of colon cancer is fluorouracil plus leucovorin (FL). Oxaliplatin improves the efficacy of this combination in patients with metastatic colorectal cancer. We evaluated the efficacy of treatment with FL plus oxaliplatin in the postoperative adjuvant setting. METHODS We randomly assigned 2246 patients who had undergone curative resection for stage II or III colon cancer to receive FL alone or with oxaliplatin for six months. The primary end point was disease-free survival. RESULTS A total of 1123 patients were randomly assigned to each group. After a median follow-up of 37.9 months, 237 patients in the group given FL plus oxaliplatin had had a cancer-related event, as compared with 293 patients in the FL group (21.1 percent vs. 26.1 percent; hazard ratio for recurrence, 0.77; P=0.002). The rate of disease-free survival at three years was 78.2 percent (95 percent confidence interval, 75.6 to 80.7) in the group given FL plus oxaliplatin and 72.9 percent (95 percent confidence interval, 70.2 to 75.7) in the FL group (P=0.002 by the stratified log-rank test). In the group given FL plus oxaliplatin, the incidence of febrile neutropenia was 1.8 percent, the incidence of gastrointestinal adverse effects was low, and the incidence of grade 3 sensory neuropathy was 12.4 percent during treatment, decreasing to 1.1 percent at one year of follow-up. Six patients in each group died during treatment (death rate, 0.5 percent). CONCLUSIONS Adding oxaliplatin to a regimen of fluorouracil and leucovorin improves the adjuvant treatment of colon cancer.</div>
</front>
</TEI>
<affiliations><list><country><li>Australie</li>
<li>Espagne</li>
<li>France</li>
<li>Italie</li>
<li>Royaume-Uni</li>
</country>
<region><li>Angleterre</li>
<li>Catalogne</li>
<li>Grand Londres</li>
<li>Île-de-France</li>
</region>
<settlement><li>Barcelone</li>
<li>Londres</li>
<li>Paris</li>
</settlement>
</list>
<tree><country name="France"><region name="Île-de-France"><name sortKey="Andre, Thierry" sort="Andre, Thierry" uniqKey="Andre T" first="Thierry" last="Andre">Thierry Andre</name>
</region>
<name sortKey="Andre, Thierry" sort="Andre, Thierry" uniqKey="Andre T" first="Thierry" last="Andre">Thierry Andre</name>
<name sortKey="De Gramont, Aimery" sort="De Gramont, Aimery" uniqKey="De Gramont A" first="Aimery" last="De Gramont">Aimery De Gramont</name>
<name sortKey="De Gramont, Aimery" sort="De Gramont, Aimery" uniqKey="De Gramont A" first="Aimery" last="De Gramont">Aimery De Gramont</name>
<name sortKey="Mounedji Boudiaf, Lamia" sort="Mounedji Boudiaf, Lamia" uniqKey="Mounedji Boudiaf L" first="Lamia" last="Mounedji-Boudiaf">Lamia Mounedji-Boudiaf</name>
<name sortKey="Tabah Fisch, Isabelle" sort="Tabah Fisch, Isabelle" uniqKey="Tabah Fisch I" first="Isabelle" last="Tabah-Fisch">Isabelle Tabah-Fisch</name>
</country>
<country name="Italie"><noRegion><name sortKey="Boni, Corrado" sort="Boni, Corrado" uniqKey="Boni C" first="Corrado" last="Boni">Corrado Boni</name>
</noRegion>
<name sortKey="Zaninelli, Marta" sort="Zaninelli, Marta" uniqKey="Zaninelli M" first="Marta" last="Zaninelli">Marta Zaninelli</name>
</country>
<country name="Espagne"><noRegion><name sortKey="Navarro, Matilde" sort="Navarro, Matilde" uniqKey="Navarro M" first="Matilde" last="Navarro">Matilde Navarro</name>
</noRegion>
<name sortKey="Tabernero, Josep" sort="Tabernero, Josep" uniqKey="Tabernero J" first="Josep" last="Tabernero">Josep Tabernero</name>
</country>
<country name="Royaume-Uni"><noRegion><name sortKey="Hickish, Tamas" sort="Hickish, Tamas" uniqKey="Hickish T" first="Tamas" last="Hickish">Tamas Hickish</name>
</noRegion>
<name sortKey="Bridgewater, John" sort="Bridgewater, John" uniqKey="Bridgewater J" first="John" last="Bridgewater">John Bridgewater</name>
<name sortKey="Topham, Clare" sort="Topham, Clare" uniqKey="Topham C" first="Clare" last="Topham">Clare Topham</name>
</country>
<country name="Australie"><noRegion><name sortKey="Clingan, Philip" sort="Clingan, Philip" uniqKey="Clingan P" first="Philip" last="Clingan">Philip Clingan</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 00AB60 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 00AB60 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:04-0317626
   |texte=   Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri